DAVENPORT & Co LLC Purchases 102 Shares of argenx SE (NASDAQ:ARGX)

DAVENPORT & Co LLC boosted its position in shares of argenx SE (NASDAQ:ARGXGet Rating) by 7.4% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,481 shares of the company’s stock after buying an additional 102 shares during the quarter. DAVENPORT & Co LLC’s holdings in argenx were worth $467,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC raised its position in argenx by 126.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $55,000 after acquiring an additional 97 shares in the last quarter. Fieldpoint Private Securities LLC raised its position in argenx by 64.8% during the first quarter. Fieldpoint Private Securities LLC now owns 440 shares of the company’s stock worth $139,000 after acquiring an additional 173 shares in the last quarter. Quadrant Capital Group LLC raised its position in argenx by 20.2% during the fourth quarter. Quadrant Capital Group LLC now owns 471 shares of the company’s stock worth $165,000 after acquiring an additional 79 shares in the last quarter. HighTower Advisors LLC bought a new stake in argenx during the fourth quarter worth $203,000. Finally, Signaturefd LLC raised its position in argenx by 20.6% during the fourth quarter. Signaturefd LLC now owns 655 shares of the company’s stock worth $229,000 after acquiring an additional 112 shares in the last quarter. 58.76% of the stock is owned by institutional investors.

argenx Trading Up 1.9 %

Shares of NASDAQ ARGX opened at $363.61 on Tuesday. The company has a 50 day simple moving average of $344.83 and a 200 day simple moving average of $312.67. argenx SE has a 1 year low of $249.50 and a 1 year high of $383.81.

argenx (NASDAQ:ARGXGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($4.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.07) by $0.71. argenx had a negative net margin of 147.47% and a negative return on equity of 32.54%. The firm had revenue of $31.48 million during the quarter, compared to analyst estimates of $12.68 million. During the same quarter last year, the business earned ($0.81) EPS. As a group, research analysts expect that argenx SE will post -19.15 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ARGX shares. JPMorgan Chase & Co. increased their price objective on shares of argenx from €390.00 ($397.96) to €430.00 ($438.78) and gave the company an “overweight” rating in a research report on Thursday, July 14th. Stifel Nicolaus assumed coverage on shares of argenx in a research report on Monday, June 27th. They issued a “buy” rating and a $460.00 price objective on the stock. Piper Sandler upped their price target on shares of argenx from $415.00 to $425.00 and gave the company an “overweight” rating in a research note on Monday. Morgan Stanley upgraded shares of argenx from an “equal weight” rating to an “overweight” rating and set a $375.00 price target on the stock in a research note on Tuesday, May 3rd. Finally, SVB Leerink restated an “outperform” rating on shares of argenx in a research note on Tuesday, May 24th. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, argenx presently has an average rating of “Buy” and an average target price of $381.67.

argenx Profile

(Get Rating)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

Featured Stories

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGXGet Rating).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.